Actions for Evaluation of biomarkers and surrogate endpoints in chronic disease

Email RIS file
Bookmark
Report an Issue

Evaluation of biomarkers and surrogate endpoints in chronic disease / Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, Board on Health Care Services, Board on Health Sciences Policy, Food and Nutrition Board, Institute of Medicine ; Christine M. Micheel and John R. Ball, editors

Published
Washington, D.C. : National Academies Press, [2010]
Copyright Date
©2010
Physical Description
1 online resource (xx, 314 pages) : illustrations
Additional Creators
Micheel, Christine, Ball, John, 1944-, and Institute of Medicine (U.S.). Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease
Access Online

Availability

I Want It
I Want It

Finding items...

Series
Language Note
English.
Contents
Review : evaluating and regulating biomarker use -- The biomarker evaluation process -- Case studies-- Strengthening evidence-based regulation.
Summary
"Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process."--Publisher's description.
Subject(s)
ISBN
9780309151306 (electronic bk.)
0309151309 (electronic bk.)
128278742X
9781282787421
0309151295 (pbk.)
9780309151290 (pbk.)
9786612787423
6612787422
0309157277
9780309157278
Digital File Characteristics
data file
Bibliography Note
Includes bibliographical references.
View MARC record | catkey: 43346484